Podcast Episodes

Oculis Announces Phase 3 Results for DME Eye Drops

Oculis Releases phase 3 data for its investigational eye drop for DME; Rayner expands its surgical offerings with the launch of a new OVD; and a bios…

11 hours ago

Outlook Wins Appeal for Wet AMD Drug Candidate Lytenava

Outlook Therapeutics takes a major step forward in its plan to gain approval for wet AMD drug Lytenava; the first commercial FLIGHT procedures using …

1 week ago

Next-Generation FSYX Goggles Approved for Glaucoma

The FDA approves wireless pressure-modulating goggles for at-home glaucoma treatment; Bausch + Lomb launches a new PreserVision AREDS eye vitamin for…

2 weeks ago

Future of Posterior Therapeutics

Leading ophthalmologists join us to discusses the hottest topics in the posterior segment treatment landscape. 

Learn more about your ad choices. Vis…

3 weeks ago

Bayer Acquires Perfuse in $2.45 Billion Deal

Bayer expands ophthalmology pipeline with acquisiton of Perfuse Therapeutics; Viridian announces new phase 3 data for its investigational subcutaneou…

4 weeks ago

How Ophthalmology Strategics are Rewriting the Playbook

Ophthalmic executives discuss strategies to scale and grow in today’s economic and regulatory environments. 

Learn more about your ad choices. Visit …

1 month ago

Glaukos Issued J-Code for Recently Launched Epioxa

Glaukos commercially launches its topical drug therapy for keratoconus; BVI’s next-generation phaco-vitrectomy surgical system receives CE Mark; and …

1 month, 1 week ago

Breaking News from the ASCRS Meeting in Washington DC

Eyewire reports on new products and breaking news live from the American Society of Cataract and Refractive Surgery meeting in Washington DC. 

Learn …

1 month, 2 weeks ago

More than 3 Million Bottles of Eye Drops Recalled

A major recall is announced for several store-brand OTC eye drops; the FDA extends dosing intervals for Eylea HD in patients with Wet AMD and DME; an…

1 month, 3 weeks ago

Biogen Enters GA Treatment Market After Major Acquisition

Pharma giant Biogen announces its intention to acquire Apellis in a multi-billion dollar deal; a recently approved first-of-its-kind presbyopia drop …

2 months ago